Markets

Palantir upgraded to ‘buy’ with a fresh $34 price target from Goldman Sachs after revealing ‘sustainable growth’ in latest earnings

Palantir posted a surprise loss in its fiscal fourth-quarter earnings on Tuesday, causing the stock to fall. Goldman Sachs analysts thought the quarter was stronger than expected and raised their price target to $US34 per share. The analysts cheered Palantir’s government revenue, margin expansion, and backlog visibility. Sign up here […]
Palantir upgraded to ‘buy’ with a fresh $34 price target from Goldman Sachs after revealing ‘sustainable growth’ in latest earnings
Markets

Palantir surges 17% after it wins FDA contract worth $44 million, report says

Palantir surged as much as 17% on Monday after a Bloomberg report said the data-mining firm won a three-year contract with the FDA worth $US44 million. Palantir’s software will help drive the FDA’s drug reviews and inspections, according to the report. Visit Business Insider’s homepage for more stories. Palantir surged […]
Palantir surges 17% after it wins FDA contract worth $44 million, report says